Hikma Pharmaceuticals PLC

HIK

GB00B0LCW083

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 06:45:35 2024-05-20 am EDT			5-day change	1st Jan Change
1,983 ^GBX	+0.25%		-1.61%	+10.65%

May. 17	HIKMA PHARMACEUTICALS : Time to capitalise on Hikma’s ongoing (share price) momentum
May. 03	Deutsche Bank Starts Hikma Pharmaceuticals Coverage at Buy	MT

Hikma Pharmaceuticals PLC - Notice of results

July 18, 2023 at 09:46 am EDT

London - Hikma Pharmaceuticals PLC (Hikma, Group), will announce its interim financial results for the six months ended 30 June 2023 on Thursday 3 August 2023.

A recording of the presentation will be available on the Group's website at www.hikma.com from 7:00am BST. Hikma will also hold a live Q&A conference call for analysts at 9:30am BST, and a recording will be made available on the Company's website.

To join via conference call please dial

United Kingdom (local): +44 20 4587 0498

United Kingdom (toll-free): +44 800 358 1035

Global Dial-In Numbers

Access Code: 317158

Contact:

Tiina Lugmayer

Email: tlugmayer@hikma.com

Latest news about Hikma Pharmaceuticals PLC

HIKMA PHARMACEUTICALS : Time to capitalise on Hikma’s ongoing (share price) momentum	May. 17
Deutsche Bank Starts Hikma Pharmaceuticals Coverage at Buy	May. 03	MT
Jefferies cuts AJ Bell; Deutsche likes ConvaTec	May. 03	AN
HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets	Apr. 26
Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024	Apr. 25	CI
Hikma Pharmaceuticals backs outlook after making strong start to 2024	Apr. 25	AN
Transcript : Hikma Pharmaceuticals PLC - Shareholder/Analyst Call	Apr. 25
Hikma Pharmaceuticals Affirms FY24 Guidance	Apr. 25	MT
Hikma Pharmaceuticals PLC Proposes Final Dividend for the Full Year 2023	Apr. 25	CI
Hikma Pharmaceuticals plc Reiterates Earnings Guidance for the Year 2024	Apr. 25	CI
Hikma Pharmaceuticals PLC Announces Executive Changes	Apr. 15	CI
FTSE 100 Closes Up 0.12% Ahead of U.K. Jobs Data	Mar. 11	DJ
The FTSE 100 Closed Up 0.4% as U.K. Announces Spring Budget Tax Cuts	Mar. 06	DJ
Rakuten Medical, Inc. announced that it has received $45 million in funding from Dai-ichi Life Holdings, Inc., Mizuho Bank, Ltd., Hikma Pharmaceuticals PLC, Rakuten Ventures, SBI Holdings, Inc., Investment Arm and another investor	Mar. 05	CI
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down	Mar. 03	MT
AFT Pharmaceuticals to Expand Global Footprint with Signing of Supply, Production Deals	Mar. 03	MT
AFT Pharmaceuticals Limited Extends License for Maxigesic/Combogesic IV with Hikma Pharmaceuticals	Mar. 03	CI
RBC Keeps Hikma Pharmaceuticals at Sector Perform, Raises PT	Feb. 29	MT
Barclays cuts Direct Line to equal weight	Feb. 29	AN
Stocks called up following slew of FTSE 100 earnings	Feb. 29	AN
Hyloris Partner Hikma Launches Pain Medication in US, Obtains Approval in Canada	Feb. 28	MT
Merck's Bridion faces generic threat from drugmaker Hikma	Feb. 26	RE
Barclays raises Breedon but cuts Domino's Pizza	Feb. 23	AN
FTSE 100 Closes Up After Nvidia Results Lead to Global Rally	Feb. 22	DJ
HIKMA PHARMACEUTICALS : Strong Generics-led finish to 2023	Feb. 22

Chart Hikma Pharmaceuticals PLC

Duration

Period

More charts

Company Profile

Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

HIKMA PHARMACEUTICALS : Time to capitalise on Hikma’s ongoing (share price) momentum

May 17, 2024 at 09:10 am EDT

More Strategies

Ratings for Hikma Pharmaceuticals PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.13 USD

Average target price

28.68 USD

Spread / Average Target

+14.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HIKMA PHARMACEUTICALS PLC	+10.65%	5.58B
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+13.87%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals